The impact of M&As on company innovation: Evidence from the US medical device industry

Scientometrics

Volumn 84, Issue 1, 2010, Pages 119-131

  Lin, Chih Hao ^a,b   Jang, Show Ling ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

M A; Patent diversity; Patent stock; US medical device industry

Indexed keywords

EID: 77953321038     PISSN: 01389130     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11192-009-0096-9     Document Type: Article

References (15)

1. Acs, Z. J., & Audretsch, D. B. (1991). Innovation and size at the firm level. Southern Economic Journal, 57(3), 739-744.
2. Arora, A., & Gambardella, A. (1990). Complementarity and external linkages: The strategies of the large firms in biotechnology. The Journal of Industrial Economics, 38(4), 361-379.
3. Cassiman, B., Colombo, M. G., Garrone, P., & Veugelers, R. (2005). The impact of M& A on the R& D process: An empirical analysis of the role of technological- and market-relatedness. Research Policy, 34, 195-220.
4. Cloodt, M., Hagedoorn, J., & van Kranenburg, H. (2006). Mergers and acqusitions: Their effect on the innovative performance of companies in high-tech industries. Research Policy, 35, 642-654.
5. Ernst & Young (2007). Ernst & Young's global biotechnology report.
6. Griliches, Z., & Mairesse, J. (1990). R& D and productivity growth: Comparing Japanese and U. S. manufacturing firms. In C. Hulten (ed.), Productivity growth in Japan and the United States Vol. 53 of NBER Studies in Income and Wealth (pp. 317-348). Chicago: University of Chicago Press.
7. Hall, L., & Bagchi-Sen, S. (2007). An analysis of firm-level innovation strategies in the U. S. biotechnology industry. Technovation, 27, 4-14.
8. Hall, B. H., Griliches, Z., & Hausman, J. A. (1986). Patent and R and D: Is there a lag? International Economic Review, 27(2), 265-283.
9. Hall, B. H., & Ziedonis, R. H. (2001). The patent paradox revisited: An empirical study of patenting in the US semiconductor industry, 1979-1995. Rand Journal, 32(1), 101-128.
10. Jang, S. L., & Huang, G. G. (2005). Public R& D and industrial innovations at the project levels: An exploration of Taiwan's public research projects. Contemporary Economic Policy, 23(4), 636-646.
11. Lerner, J., & Merges, R. P. (1998). The control of technology alliances: An empirical analysis of the biotechnology industry. The Journal of Industrial Economics, 46(2), 125-156.
12. MD& DI's Industry Yearbook. (2005). The Biotech Communications Group, Inc.
13. Nesta, L. & Saviotti P. (2004). Coherence of the knowledge base and firm innovative performance: Evidence from the U. S. pharmaceutical industry. SPRU Working Paper, 113.
14. Patel, P., & Pavitt, K. (1997). The technological competencies of the world's largest firms: Complex and path-dependent, but not much variety. Research Policy, 26, 141-156.
15. Roijakkers, N., & Hagedoorn, J. (2006). Inter-firm R& D partnering in pharmaceutical biotechnology since 1975: Trends, patterns and networks. Research Policy, 35(3), 431-446.